Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...

Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...